BR112015021985A2 - compostos e seus usos para a modulação de hemoglobina - Google Patents
compostos e seus usos para a modulação de hemoglobinaInfo
- Publication number
- BR112015021985A2 BR112015021985A2 BR112015021985A BR112015021985A BR112015021985A2 BR 112015021985 A2 BR112015021985 A2 BR 112015021985A2 BR 112015021985 A BR112015021985 A BR 112015021985A BR 112015021985 A BR112015021985 A BR 112015021985A BR 112015021985 A2 BR112015021985 A2 BR 112015021985A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- ring
- independently
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
relatório descritivo da patente de invenção para "compostos e seus usos para a modulação de hemoglobina" domínio da invenção [0001] esta invenção proporciona compostos e composições farmacêuticas adequados como moduladores alostéricos de hemoglobina, métodos e intermediários para a sua preparação, e métodos para o seu uso no tratamento de distúrbios mediados por hemoglobina e distúrbios que irão beneficiar de oxigenação tecidual e/ou celular. estado da técnica [0002] a doença de células falciformes é um distúrbio dos eritrócitos, que se encontra particularmente entre descendentes africanos e mediterrânicos. a base da doença de células falciformes se encontra em hemoglobina falciforme (hbs), que contém uma mutação pontual relativamente à sequência peptídica prevalecente da hemoglobina (hb). [0003] a hemoglobina (hb) transporta moléculas de oxigênio dos pulmões para vários tecidos e órgãos em todo o corpo. a hemoglobina se liga e libera oxigênio através de alterações conformacionais. a hemoglobina falciforme (hbs) contém uma mutação pontual pela qual ácido glutâmico é substituído por valina, permitindo que a hbs se torne suscetível a polimerização, dotando os eritrócitos contendo hbs de sua forma falciforme característica. as células falciformes também são mais rígidas do que eritrócitos normais, e sua falta de flexibilidade pode conduzir a bloqueio de vasos sanguíneos. us 7,160,910 divulga compostos que são moduladores alostéricos de hemoglobina. no entanto, são necessários agentes terapêuticos adicionais que possam tratar distúrbios que são mediados por hb ou por hb anormal, como hbs. sumário da invenção [0004] esta invenção refere-se genericamente a compostos e composições farmacêuticas adequados como moduladores alostéricos de hemoglobina. em alguns aspectos, esta invenção refere-se a métodos para tratar distúrbios mediados por hemoglobina e distúrbios que irão beneficiar de oxigenação tecidual e/ou celular. [0005] em certos aspectos da invenção, é proporcionado um composto da fórmula (a): (a) ou um respectivo tautômero, ou um sal farmaceuticamente aceitável de cada um daqueles ou um respectivo sal farmaceuticamente aceitável, em que l1 é uma ligação ou é nr70, o, s, ou (cr71r72)d; em que cada r70, r71, e r72 independentemente é hidrogênio ou c1-c6 alquila; d é 1, 2 ou 3; l2 é c=o ou so2; cada y e z é independentemente cr10r11, o, s, so, so2, ou nr10; cada r10 e r11 é independentemente hidrogênio ou c1-c3 alquila opcionalmente substituído com 1-3 halo, oh, ou c1-c6 alcoxi, ou cr10r11 é c=o, desde que, se um de y e z for o, s, so, so2, então o outro não é co, e y e z não são ambos heteroátomos ou respectivas formas oxidadas; em que y está ? ou ? substituído relativamente a l1l2r3; em que z e cv1v2h são unidos a átomos adjacentes no anel c; v1 e v2 independentemente são c1-c6 alcoxi; ou v1 e v2, em conjunto com o átomo de carbono ao qual estão ligados, formam um anel da fórmula: em que cada v3 e v4 é independentemente o, s, ou nh, desde que, quando um de v3 e v4 é s, o outro seja nh, e desde que v3 e v4 não sejam ambos nh; q é 1 ou 2; cada v5 é independentemente c1-c6 alquila ou co2r60, em que cada r60, independentemente, é c1-c6 alquila ou hidrogênio; t é 0, 1, 2, ou 4; ou cv1v2 é c=v, em que v é o, nor80, ou nnr81r82; r80 é c1-c6 alquila opcionalmente substituído; r81 e r82, independentemente, são selecionados do grupo consistindo de hidrogênio, c1-c6 alquila opcionalmente substituído, cor83 e co2r84; r83 é hidrogênio ou c1-c6 alquila opcionalmente substituído; e r84 é c1-c6 alquila opcionalmente substituído, e r3, b, e c são definidos do modo seguinte. [0006] em um caso, r3 é c1-c6 alquila, c3-c8 cicloalquila, c1-c6 alcoxi, c3-c8 cicloalcoxi, ou nr1r2; cada r1 e r2 independentemente é hidrogênio, c1-c6 alquila, c3-c8 cicloalquila, c6-c10 arila, heterociclo de 4-10 membros ou heteroarila de 5-10 membros, cada um contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s, em que cada alquila, cicloalquila, heterociclo, arila ou heteroarila está opcionalmente substituído, ou r1 e r2, em conjunto com o átomo de nitrogênio ao qual estão ligados, formam um heterociclo de 4-7 membros opcionalmente substituído; o anel b é um c6-c10 arila opcionalmente substituído, heteroarila de 5-10 membros opcionalmente substituído tendo 1-3 átomos de nitrogênio ou formas oxidadas de n, ou heterociclo de 4-10 membros opcionalmente substituído contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s; e o anel c é um c6-c10 arila opcionalmente substituído ou heteroarila de 5-10 membros opcionalmente substituído contendo 1-3 átomos de nitrogênio, ou uma forma oxidada de n, em que certos substituintes preferenciais incluem oh, halo, c1-c6 alcoxi, c3-c6 cicloalcoxi ou o-r, em que r é uma fração de pró-fármaco, em que o c1-c6 alcoxi está opcionalmente substituído com 1-5 halo. [0007] em outro caso, r3 é c6-c10 arila, ou um heteroarila de 5-10 membros, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s, em que cada um do arila, ou heteroarila está opcionalmente substituído com 1-4 c1-c6 alquila; o anel b é um heterociclo de 4-10 membros opcionalmente substituído contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s; o anel c é c6-c10 arila ou um heteroarila de 5-10 membros contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s, cada um dos quais está opcionalmente substituído com 1-4: halo, oxo, -or19, c1-c6 alquila, e/ou c1-c6 alcoxi, em que o c1-c6 alquila está opcionalmente substituído com 1-5 halo, c1-c6 alcoxi e/ou um heterociclo de 4-10 membros contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s, em que certos substituintes preferenciais incluem oh, halo, c1-c6 alcoxi, c3-c6 cicloalcoxi ou o-r, em que r é uma fração de pró-fármaco, em que o c1-c6 alcoxi está opcionalmente substituído com 1-5 halo; e r19 é hidrogênio ou uma fração de pró-fármaco r. [0008] em certos aspectos da invenção, é proporcionado um composto da fórmula (ii): (ii) ou um respectivo tautômero, ou respectivo sal farmaceuticamente aceitável de cada, em que r3 é c1-c6 alquila, c3-c8 cicloalquila, c1-c6 alcoxi, c3-c8 cicloalcoxi, ou nr1r2; cada r1 e r2 independentemente é hidrogênio, c1-c6 alquila, c3-c8 cicloalquila, c6-c10 arila, heterociclo de 4-10 membros ou heteroarila de 5-10 membros, cada um contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s, em que cada alquila, cicloalquila, heterociclo, arila ou heteroarila está opcionalmente substituído, ou r1 e r2, em conjunto com o átomo de nitrogênio ao qual estão ligados, formam um heterociclo de 4-7 membros opcionalmente substituído; l é uma ligação ou é nr70, o, s, ou (cr71r72)d; em que cada r70, r71, e r72, independentemente, é hidrogênio ou c1-c6 alquila; d é 1, 2 ou 3; o anel b é um c6-c10 arila opcionalmente substituído, heteroarila de 5-10 membros opcionalmente substituído tendo 1-3 átomos de nitrogênio ou formas oxidadas de n, ou heterociclo de 4-10 membros opcionalmente substituído contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s; cada y e z é independentemente cr10r11, o, s, so, so2, ou nr10; cada r10 e r11 é independentemente hidrogênio ou c1-c3 alquila opcionalmente substituído com 1-3 halo, oh, ou c1-c6 alcoxi, ou cr10r11 é c=o, desde que, se um de y e z for o, s, so, so2, então o outro não é co, e y e z não são ambos heteroátomos ou respectivas formas oxidadas; em que y está ? ou ? substituído relativamente a lcor3; o anel c é um c6-c10 arila opcionalmente substituído ou heteroarila de 5-10 membros opcionalmente substituído contendo 1-3 átomos de nitrogênio, ou uma forma oxidada de n; em que z e cv1v2h são unidos a átomos adjacentes no anel c; v1 e v2 independentemente são c1-c6 alcoxi; ou v1 e v2, em conjunto com o átomo de carbono ao qual estão ligados, formam um anel da fórmula: em que cada v3 e v4 é independentemente o, s, ou nh, desde que, quando um de v3 e v4 é s, o outro seja nh, e desde que v3 e v4 não sejam ambos nh; q é 1 ou 2; cada v5 é independentemente c1-c6 alquila ou co2r60, em que cada r60, independentemente, é c1-c6 alquila ou hidrogênio; t é 0, 1, 2, ou 4; ou cv1v2 é c=v, em que v é o, nor80, ou nnr81r82; r4 é oh, halo, c1-c6 alcoxi, c3-c6 cicloalcoxi ou o-r, em que r é uma fração de pró-fármaco, em que o c1-c6 alcoxi está opcionalmente substituído com 1-5 halo; r80 é c1-c6 alquila opcionalmente substituído; r81 e r82, independentemente, são selecionados do grupo consistindo de hidrogênio, c1-c6 alquila opcionalmente substituído, cor83 e co2r84; r83 é hidrogênio ou c1-c6 alquila opcionalmente substituído; e r84 é c1-c6 alquila opcionalmente substituído. [0009] em certos aspectos da invenção, é proporcionado um composto da fórmula (iv): (iv) em que r3 é c6-c10 arila, ou um heteroarila de 5-10 membros, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s, em que cada um do arila, ou heteroarila está opcionalmente substituído com 1-4: c1-c6 alquila; l1 é uma ligação ou é nr70, o, s, ou (cr71r72)d; em que cada r70, r71, e r72 independentemente é hidrogênio ou c1-c6 alquila; d é 1, 2 ou 3; l2 é c=o ou so2; o anel b é um heterociclo de 4-10 membros opcionalmente substituído contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s; cada y e z é independentemente (cr10r11)e, o, s, so, so2, ou nr10; e é 1 até 4, preferencialmente 1; cada r10 e r11 independentemente é hidrogênio ou c1-c3 alquila opcionalmente substituído com 1-3 halo, oh, ou c1-c6 alcoxi, ou cr10r11 é c=o, desde que, se um de y e z for o, s, so, so2, então o outro não é co, e y e z não são ambos heteroátomos ou respectivas formas oxidadas; em que y está ? ou ? substituído relativamente a l1l2r3; o anel c é c6-c10 arila ou um heteroarila de 5-10 membros contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s, cada um dos quais está opcionalmente substituído com 1-4: halo, oxo, -or2, c1-c6 alquila, e/ou c1-c6 alcoxi, em que o c1-c6 alquila está opcionalmente substituído com 1-5 halo, c1-c6 alcoxi e/ou um heterociclo de 4-10 membros contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s; r2 é hidrogênio ou uma fração de pró-fármaco r; e em que z e cv1v2h são ligados a átomos adjacentes no anel c; v1 e v2 independentemente são c1-c6 alcoxi; ou v1 e v2, em conjunto com o átomo de carbono ao qual estão ligados, formam um anel da fórmula: em que cada v3 e v4 é independentemente o, s, ou nh, desde que, quando um de v3 e v4 é s, o outro seja nh, e desde que v3 e v4 não sejam ambos nh; q é 1 ou 2; cada v5 é independentemente c1-c6 alquila ou co2r60, em que cada r60, independentemente, é c1-c6 alquila ou hidrogênio; t é 0, 1, 2, ou 4; ou cv1v2 é c=v, em que v é o, nor80, ou nnr81r82; r80 é c1-c6 alquila opcionalmente substituído; r81 e r82, independentemente, são selecionados do grupo consistindo de hidrogênio, c1-c6 alquila opcionalmente substituído, cor83 e co2r84; r83 é hidrogênio ou c1-c6 alquila opcionalmente substituído; e r84 é c1-c6 alquila opcionalmente substituído. [0010] em uma modalidade, o anel b é unido a l1 ou l2 via um átomo de nitrogênio. em outra modalidade, r3 é unido a l2 via um átomo de nitrogênio. [0011] em aspectos adicionais da invenção, é proporcionada uma composição compreendendo qualquer um dos compostos descritos aqui, e pelo menos um excipiente farmaceuticamente aceitável. [0012] ainda em outros aspectos da invenção, é proporcionado um método para aumentar a afinidade para oxigênio de hemoglobina s em um sujeito, em que o método compreende administrar a um sujeito necessitado uma quantidade terapeuticamente eficaz de qualquer um dos compostos ou composições descritos aqui. [0013] em aspectos adicionais da invenção, é proporcionado um método para tratar deficiência de oxigênio associada a anemia de células falciformes, em que o método compreende administrar a um sujeito necessitado uma quantidade terapeuticamente eficaz de qualquer um dos compostos ou composições descritos aqui. descrição detalhada da invenção definições [0014] deve ser notado que, como usado aqui e nas reivindicações adjuntas, as formas singulares "um", "uma" e "o", "a" incluem referentes plurais, a menos que o contexto claramente imponha o contrário. assim, por exemplo, referência a um solvente inclui uma pluralidade de tais solventes. [0015] como usado aqui, é pretendido que o termo compreendendo ou compreende signifique que as composições e métodos incluem os elementos apresentados, mas não excluindo outros. consistindo essencialmente de, quando usado para definir composições e métodos, significa excluir outros elementos de qualquer importância essencial para a combinação para o propósito apresentado. assim, uma composição ou processo consistindo essencialmente dos elementos como definido aqui não exclui outros materiais ou etapas que não afetem materialmente a(s) característica(s) básica(s) e nova(s) da invenção reivindicada. consistindo de significa excluir mais do que elementos traço de outros ingredientes e etapas de métodos substanciais. modalidades definidas por cada um destes termos de transição pertencem ao escopo desta invenção. [0016] a menos que indicado em contrário, todos os números expressando quantidades de ingredientes, condições reacionais, e assim por diante usados na especificação e reivindicações devem ser entendidos como estando modificados em todos os casos pelo termo cerca de. em conformidade, a menos que indicado em contrário, os parâmetros numéricos apresentados na seguinte especificação e reivindicações adjuntas são aproximações. cada parâmetro numérico deve ser pelo menos considerado à luz do número de dígitos significativos relatados e aplicando técnicas comuns de arredondamento. o termo cerca de, quando usado antes de uma designação numérica, por exemplo, temperatura, tempo, quantidade, e concentração, incluindo intervalo, indica aproximações que podem variar por ( + ) ou ( - ) 10 %, 5 % ou 1 %. [0017] como usado aqui, cm-cn, como c1-c12, c1-c8, ou c1-c6, quando usado antes de um grupo, refere-se a esse grupo contendo m até n átomos de carbono. [0018] o termo alcoxi refere-se a o-alquila. cicloalcoxi refere-se a o-cicloalquila. [0019] o termo alquila refere-se a grupos hidrocarbila alifáticos saturados monovalentes tendo desde 1 até 30 átomos de carbono (isto é, c1-c30 alquila) ou 1 até 22 átomos de carbono (isto é, c1-c22 alquila), 1 até 8 átomos de carbono (isto é, c1-c8 alquila), ou 1 até 4 átomos de carbono. este termo inclui, a título de exemplo, grupos hidrocarbila lineares e ramificados, como metila (ch3-), etila (ch3ch2-), n-propila (ch3ch2ch2-), isopropila ((ch3)2ch-), n-butila (ch3ch2ch2ch2-), isobutila ((ch3)2chch2-), sec-butila ((ch3)(ch3ch2)ch-), t-butila ((ch3)3c-), n-pentila (ch3ch2ch2ch2ch2-), e neopentila ((ch3)3cch2-). [0020] o termo arila refere-se a um anel mono- ou bicíclico monovalente aromático tendo 6-10 átomos de carbono de anel. exemplos de arila incluem fenila e naftila. o anel condensado pode ou não ser aromático, desde que o ponto de ligação seja em um átomo de carbono aromático. por exemplo, e sem limitação, o seguinte é um grupo arila: . [0021] o termo éster -co2h refere-se a um éster formado entre o grupo co2h e um álcool, preferencialmente um álcool alifático. um exemplo preferencial inclui co2re, em que re é um grupo alquila ou arila opcionalmente substituído com um grupo amino. [0022] o termo fração quiral refere-se a uma fração que é quiral. tal fração pode possuir um ou mais centros assimétricos. preferencialmente, a fração quiral é enantiomericamente enriquecida, e mais preferencialmente é um único enantiômero. exemplos não limitativos de frações quirais incluem ácidos carboxílicos quirais, aminas quirais, aminoácidos quirais, como os aminoácidos de ocorrência natural, álcoois quirais incluindo esteroides quirais, e similares. [0023] o termo cicloalquila refere-se a um anel hidrocarbila mono-, bi-, ou tricíclico monovalente, preferencialmente saturado, tendo 3-12 átomos de carbono de anel. não obstante cicloalquila se referir preferencialmente a anéis hidrocarbila saturados, como usado aqui, também inclui anéis contendo 1-2 ligações duplas carbono-carbono. exemplos não limitativos de cicloalquila incluem ciclopropila, ciclobutila, ciclopentila, ciclohexila, cicloheptila, adamentila, e similares. os anéis condensados podem ou não ser anéis hidrocarbila não aromáticos desde que o ponto de ligação seja em um átomo de carbono de cicloalquila. por exemplo, e sem limitação, o seguinte é um grupo cicloalquila: . [0024] o termo halo refere-se a f, cl, br, e/ou i. [0025] o termo heteroarila refere-se a um anel aromático monovalente mono-, bi-, ou tricíclico tendo 2-16 átomos de carbono de anel e 1-8 heteroátomos de anel selecionados preferencialmente de n, o, s, e p e formas oxidadas de n, s, e p, desde que o anel contenha pelo menos 5 átomos de anel. exemplos não limitativos de heteroarila incluem furano, imidazol, oxadiazol, oxazol, piridina, quinolina, e similares. os anéis condensados podem ou não ser um anel aromático contendo heteroátomo desde que o ponto de ligação seja um átomo de heteroarila. por exemplo, e sem limitação, o seguinte é um grupo heteroarila: . [0026] o termo heterociclila ou heterociclo refere-se a um anel não aromático, mono-, bi-, ou tricíclico contendo 2-12 átomos de carbono de anel e 1-8 heteroátomos de anel selecionados preferencialmente de n, o, s, e p e formas oxidadas de n, s, e p, desde que o anel contenha pelo menos 3 átomos de anel. não obstante heterociclila se referir preferencialmente a sistemas de anéis saturados, também inclui sistemas de anéis contendo 1-3 ligações duplas, desde que o anel não seja aromático. exemplos não limitativos de heterociclila incluem azalactonas, oxazolina, piperidinila, piperazinila, pirrolidinila, tetrahidrofuranila, e tetrahidropiranila. os anéis condensados podem ou não conter um anel não aromático contendo heteroátomo desde que o ponto de ligação seja um grupo heterociclila. por exemplo, e sem limitação, o seguinte é um grupo heterociclila: . [0027] o termo hidrólise refere-se à quebra de uma fração rho-co-, rh-o-cs-, ou rho-so2- em um rhoh, preferencialmente por adição de água através da ligação quebrada. uma hidrólise é realizada usando vários métodos bem conhecidos do técnico experimentado, cujos exemplos não limitativos incluem hidrólise acídica e básica. [0028] o termo oxo refere-se a um grupo c=o, e a uma substituição de 2 átomos de hidrogênio geminais com um grupo c=o. [0029] o termo opcionalmente substituído refere-se a um grupo substituído ou não substituído. o grupo pode estar substituído com um ou mais substituintes, como, por exemplo, 1, 2, 3, 4 ou 5 substituintes. preferencialmente, os substituintes são selecionados do grupo consistindo de oxo, halo, -cn, no2, -n2+, -co2r100, -or100, -sr100, -sor100, -so2r100, -nr101r102, -conr101r102, -so2nr101r102, c1-c6 alquila, c1-c6 alcoxi, -cr100=c(r100)2, -ccr100, c3-c10 cicloalquila, c3-c10 heterociclila, c6-c12 arila e c2-c12 heteroarila, em que cada r100 independentemente é hidrogênio ou c1-c8 alquila; c3-c12 cicloalquila; c3-c10 heterociclila; c6-c12 arila; ou c2-c12 heteroarila; em que cada alquila, cicloalquila, heterociclila, arila, ou heteroarila está opcionalmente substituído com 1-3 halo, 1-3 c1-c6 alquila, 1-3 c1-c6 haloalquila ou 1-3 grupos c1-c6 alcoxi. preferencialmente, os substituintes são selecionados do grupo consistindo de cloro, fluoro, -och3, metila, etila, iso-propila, ciclopropila, vinila, etinila, -co2h, -co2ch3, -ocf3, -cf3 e -ochf2. [0030] r101 e r102, independentemente, são hidrogênio; c1-c8 alquila, opcionalmente substituído com -co2h ou um respectivo éster, c1-c6 alcoxi, oxo, -cr103=c(r103)2, -ccr, c3-c10 cicloalquila, c3-c10 heterociclila, c6-c12 arila, ou c2-c12 heteroarila, em que cada r103 independentemente é hidrogênio ou c1-c8 alquila; c3-c12 cicloalquila; c3-c10 heterociclila; c6-c12 arila; ou c2-c12 heteroarila; em que cada cicloalquila, heterociclila, arila, ou heteroarila está opcionalmente substituído com 1-3 grupos alquila ou 1-3 grupos halo, ou r101 e r102, em conjunto com o átomo de nitrogênio ao qual estão ligados, formam um heterociclo de 5-7 membros. [0031] o termo farmaceuticamente aceitável refere-se a seguro e não tóxico para administração in vivo, preferencialmente humana. [0032] o termo sal farmaceuticamente aceitável refere-se a um sal que é farmaceuticamente aceitável. [0033] o termo sal refere-se a um composto iônico formado entre um ácido e uma base. quando o composto proporcionado aqui contém uma funcionalidade acídica, tais sais incluem, sem limitação, sais de metais alcalinos, metais alcalinoterrosos, e amônio. como usado aqui, sais de amônio incluem sais contendo bases nitrogenadas protonadas e bases nitrogenadas alquiladas. cátions exemplares, e não limitativos úteis em sais farmaceuticamente aceitáveis incluem cátions na, k, rb, cs, nh4, ca, ba, imidazólio, e amônio baseados em aminoácidos de ocorrência natural. quando os compostos usados aqui contêm uma funcionalidade básica, tais sais incluem, sem limitação, sais de ácidos orgânicos, como ácidos carboxílicos e ácidos sulfônicos, e ácidos minerais, como haletos de hidrogênio, ácido sulfúrico, ácido fosfórico, e similares. ânions exemplares e não limitativos úteis em sais farmaceuticamente aceitáveis incluem oxalato, maleato, acetato, propionato, succinato, tartarato, cloreto, sulfato, bisalfato, fosfato mono-, di-, e tribásico, mesilato, tosilato, e similares. [0034] os termos tratar, tratando ou tratamento, como usados aqui, incluem aliviar, mitigar ou melhorar uma doença ou estado clínico ou um ou mais sintomas do mesmo, prevenir sintomas adicionais, melhorar ou prevenir as causas metabólicas subjacentes dos sintomas, inibir a doença ou estado clínico, por exemplo, travar ou suprimir o desenvolvimento da doença ou estado clínico, acalmar a doença ou estado clínico, causar regressão da doença ou estado clínico, atenuar um estado clínico causado pela doença ou estado clínico, ou suprimir os sintomas da doença ou estado clínico, e é pretendido que incluam profilaxia. os termos também incluem atenuar a doença ou estados clínicos, por exemplo, causando a regressão de sintomas clínicos. os termos incluem adicionalmente alcançar um benefício terapêutico e/ou um benefício profilático. por benefício terapêutico pretende-se significar erradicação ou melhoria do distúrbio subjacente sendo tratado. além disso, um benefício terapêutico é alcançado com a erradicação ou melhoria de um ou mais dos sintomas fisiológicos associados ao distúrbio subjacente, de modo que uma melhoria é observada no indivíduo, não obstante o indivíduo ainda estar afetado com o distúrbio subjacente. para benefício profilático, as composições são administradas a um indivíduo em risco de desenvolver uma doença particular, ou a um indivíduo relatando um ou mais dos sintomas fisiológicos de uma doença, mesmo que ainda não tenha sido feito um diagnóstico desta doença. [0035] os termos prevenindo ou prevenção referem-se a uma redução do risco de contrair uma doença ou distúrbio (isto é, fazendo com que pelo menos um dos sintomas clínicos da doença não se desenvolva em um sujeito que pode estar exposto ou predisposto à doença mas que ainda não sente nem exibe sintomas da doença). os termos incluem adicionalmente fazer com que os sintomas clínicos não se desenvolvam, por exemplo, em um sujeito em risco de sofrer de tal doença ou distúrbio, desse modo afastando substancialmente o surgimento da doença ou distúrbio. [0036] o termo quantidade eficaz refere-se a uma quantidade que é eficaz para o tratamento de um estado clínico ou distúrbio por uma administração intranasal de um composto ou composição descrito aqui. em algumas modalidades, uma quantidade eficaz de qualquer uma das composições ou formas galênicas descritas aqui é a quantidade usada para tratar um distúrbio mediado por hemoglobina ou um distúrbio que irá beneficiar de oxigenação tecidual e/ou celular de qualquer uma das composições ou formas galênicas descritas aqui em um sujeito necessitado. [0037] o termo transportador, como usado aqui, refere-se a compostos químicos ou agentes relativamente não tóxicos que facilitam a incorporação de um composto em células, por exemplo, eritrócitos, ou tecidos. [0038] como usado aqui, um pró-fármaco é um composto que, após a administração, é metabolizado ou convertido de outro modo em uma forma ativa ou mais ativa no que se refere a pelo menos uma propriedade. para produzir um pró-fármaco, um composto farmaceuticamente ativo pode ser quimicamente modificado de modo a torná-lo menos ativo ou inativo, mas a modificação química é tal que uma forma ativa do composto é gerada por processos metabólicos ou outros processos biológicos. um pró-fármaco pode ter, relativamente ao fármaco, estabilidade metabólica ou características de transporte alteradas, menos efeitos secundários ou menor toxicidade. por exemplo, ver a referência nogrady, 1985, medicinal chemistry a biochemical approach, oxford university press, nova iorque, páginas 388-392. pró-fármacos também podem ser preparados usando compostos que não são fármacos. compostos [0039] em certos aspectos da invenção, é proporcionado um composto da fórmula (i): (i) ou um respectivo tautômero, ou um sal farmaceuticamente aceitável de cada um daqueles ou um respectivo sal farmaceuticamente aceitável, em que l1 é uma ligação ou é nr70, o, s, ou (cr71r72)d; em que cada r70, r71, e r72 independentemente é hidrogênio ou c1-c6 alquila; d é 1, 2 ou 3; l2 é c=o ou so2; cada y e z é independentemente cr10r11, o, s, so, so2, ou nr10; cada r10 e r11 é independentemente hidrogênio ou c1-c3 alquila opcionalmente substituído com 1-3 halo, oh, ou c1-c6 alcoxi, ou cr10r11 é c=o, desde que, se um de y e z for o, s, so, so2, então o outro não é co, e y e z não são ambos heteroátomos ou respectivas formas oxidadas; em que y está ? ou ? substituído relativamente a l1l2r3; em que z e cv1v2h são unidos a átomos adjacentes no anel c; v1 e v2 independentemente são c1-c6 alcoxi; ou v1 e v2, em conjunto com o átomo de carbono ao qual estão ligados, formam um anel da fórmula: em que cada v3 e v4 é independentemente o, s, ou nh, desde que, quando um de v3 e v4 é s, o outro seja nh, e desde que v3 e v4 não sejam ambos nh; q é 1 ou 2; cada v5 é independentemente c1-c6 alquila ou co2r60, em que cada r60, independentemente, é c1-c6 alquila ou hidrogênio; t é 0, 1, 2, ou 4; ou cv1v2 é c=v, em que v é o, nor80, ou nnr81r82; r4 é oh, halo, c1-c6 alcoxi, c3-c6 cicloalcoxi ou o-r, em que r é uma fração de pró-fármaco, em que o c1-c6 alcoxi está opcionalmente substituído com 1-5 halo; r80 é c1-c6 alquila opcionalmente substituído; r81 e r82, independentemente, são selecionados do grupo consistindo de hidrogênio, c1-c6 alquila opcionalmente substituído, cor83 e co2r84; r83 é hidrogênio ou c1-c6 alquila opcionalmente substituído; e r84 é c1-c6 alquila opcionalmente substituído. e r3, b, e c são definidos do modo seguinte. [0040] em um caso, r3 é c1-c6 alquila, c3-c8 cicloalquila, c1-c6 alcoxi, c3-c8 cicloalcoxi, ou nr1r2; cada r1 e r2 independentemente é hidrogênio, c1-c6 alquila, c3-c8 cicloalquila, c6-c10 arila, heterociclo de 4-10 membros ou heteroarila de 5-10 membros, cada um contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s, em que cada alquila, cicloalquila, heterociclo, arila ou heteroarila está opcionalmente substituído, ou r1 e r2, em conjunto com o átomo de nitrogênio ao qual estão ligados, formam um heterociclo de 4-7 membros opcionalmente substituído; o anel b é um c6-c10 arila opcionalmente substituído, heteroarila de 5-10 membros opcionalmente substituído tendo 1-3 átomos de nitrogênio ou formas oxidadas de n, ou heterociclo de 4-10 membros opcionalmente substituído contendo até 5 heteroátomos de anel, em que o heteroátomo é selecionado do grupo consistindo de o, n, s, e formas oxidadas de n e s; e o anel c é um c6-c10 arila opcionalmente substituído ou heteroarila de 5-10 membros opcionalmente substituído contendo 1-3 átomos de nitrogênio, ou uma forma oxidada de n; [0041] em outro caso, r3 é c6-c10 arila, ou u
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/815,735 US8952171B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
US13/815,735 | 2013-03-15 | ||
US201361905803P | 2013-11-18 | 2013-11-18 | |
US61/905,803 | 2013-11-18 | ||
PCT/US2014/022769 WO2014150268A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015021985A2 true BR112015021985A2 (pt) | 2017-07-18 |
BR112015021985B1 BR112015021985B1 (pt) | 2022-12-13 |
Family
ID=51580732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015021985-3A BR112015021985B1 (pt) | 2013-03-15 | 2014-03-10 | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição |
Country Status (22)
Country | Link |
---|---|
US (3) | US20160083343A1 (pt) |
EP (1) | EP2970196B1 (pt) |
JP (3) | JP6426694B2 (pt) |
KR (1) | KR102280614B1 (pt) |
CN (2) | CN112500338A (pt) |
AP (1) | AP2015008721A0 (pt) |
AU (3) | AU2014237340C1 (pt) |
BR (1) | BR112015021985B1 (pt) |
CA (1) | CA2903220C (pt) |
CL (1) | CL2015002501A1 (pt) |
EA (1) | EA034922B1 (pt) |
ES (1) | ES2852054T3 (pt) |
IL (1) | IL241060B (pt) |
MX (1) | MX2015011445A (pt) |
MY (1) | MY191087A (pt) |
PE (1) | PE20161035A1 (pt) |
SA (2) | SA515361026B1 (pt) |
SG (2) | SG10201802911RA (pt) |
TW (1) | TWI695830B (pt) |
UY (1) | UY35426A (pt) |
WO (1) | WO2014150268A1 (pt) |
ZA (1) | ZA201703791B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6242810B2 (ja) | 2011-12-28 | 2017-12-06 | グローバル・ブラッド・セラピューティクス・インコーポレイテッドGlobal Blood Therapeutics,Inc. | 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法 |
EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
CN105246477A (zh) | 2013-03-15 | 2016-01-13 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
MX2015011448A (es) | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
CA2903220C (en) * | 2013-03-15 | 2023-01-24 | Qing Xu | Aldehyde compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
WO2016043849A2 (en) * | 2014-07-24 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds for treating acute respiratory distress syndrome or a negative effect thereof |
MA41841A (fr) * | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
ES2966707T3 (es) * | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
MX2021005887A (es) | 2018-11-19 | 2021-09-14 | Global Blood Therapeutics Inc | Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina. |
CR20210284A (es) | 2018-11-29 | 2021-07-09 | Pfizer | Pirazoles como modulares de hemoglobina |
EP4126832A1 (en) | 2020-03-31 | 2023-02-08 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (435)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE258226C (pt) | ||||
DE276479C (pt) | ||||
DE226590C (pt) | ||||
NL214523A (pt) | 1956-02-13 | 1900-01-01 | ||
BE787580A (fr) | 1971-08-13 | 1973-02-14 | Hoechst Ag | Procede de preparation de derives du furanne |
BE787576A (fr) | 1971-08-13 | 1973-02-14 | Hoechst Ag | Derives de benzofuranne et leur utilisation comme azureurs optiques |
GB1409865A (en) | 1973-02-13 | 1975-10-15 | Science Union & Cie | Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them |
US4062858A (en) | 1976-12-22 | 1977-12-13 | E. R. Squibb & Sons, Inc. | Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines |
GB1593417A (en) | 1976-12-22 | 1981-07-15 | Squibb & Sons Inc | Carbocyclic-fused pyrazolopyridine derivatives |
EP0010063B1 (de) | 1978-10-04 | 1982-12-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von Furanyl-benzazolen |
DE2853765A1 (de) | 1978-12-13 | 1980-06-26 | Bayer Ag | Verfahren zur herstellung von benzimidazolylbenzofuranen |
DE2904829A1 (de) | 1979-02-08 | 1980-08-14 | Bayer Ag | Verfahren zur herstellung von benzimidazolylbenzofuran |
EP0022229B1 (en) * | 1979-06-29 | 1982-12-08 | The Wellcome Foundation Limited | Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof |
ZA818741B (en) * | 1980-12-18 | 1983-07-27 | Wellcome Found | Pharmaceutical compounds,preparation,use and intermediates therefor and their preparation |
JPS5929667A (ja) | 1982-08-13 | 1984-02-16 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体および強心剤 |
US4478834A (en) | 1983-02-11 | 1984-10-23 | Usv Pharmaceutical Corporation | Dihydropyridines and their use in the treatment of asthma |
GB8402740D0 (en) | 1984-02-02 | 1984-03-07 | Scras | Furo-(3 4-c)-pyridine derivatives |
JPS6140236A (ja) | 1984-08-02 | 1986-02-26 | Yamanouchi Pharmaceut Co Ltd | ハイドロキノン誘導体 |
DE3431004A1 (de) | 1984-08-23 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung |
GB8603475D0 (en) | 1986-02-12 | 1986-03-19 | Glaxo Group Ltd | Chemical compounds |
DK111387A (da) | 1986-03-05 | 1987-09-06 | Otsuka Pharma Co Ltd | Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne |
US4831041A (en) | 1986-11-26 | 1989-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
AU598093B2 (en) | 1987-02-07 | 1990-06-14 | Wellcome Foundation Limited, The | Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
JPH07121937B2 (ja) | 1987-03-18 | 1995-12-25 | 大塚製薬株式会社 | カルボスチリル誘導体 |
JPS63258463A (ja) * | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | 2−フエノキシピリミジン誘導体及び除草剤 |
GB8711802D0 (en) | 1987-05-19 | 1987-06-24 | Fujisawa Pharmaceutical Co | Dithioacetal compounds |
GB8718940D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
US4920131A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
JP2650038B2 (ja) | 1988-01-27 | 1997-09-03 | サントリー株式会社 | ピロリチジン化合物およびその用途 |
JPH01305081A (ja) | 1988-04-04 | 1989-12-08 | E R Squibb & Sons Inc | 3―アシルアミノ―1―[[[(置換スルホニル)アミノ〕カルボニル〕アミノ〕―2―アゼチジノン類 |
US4952574A (en) | 1988-09-26 | 1990-08-28 | Riker Laboratories, Inc. | Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides |
IE81170B1 (en) | 1988-10-21 | 2000-05-31 | Zeneca Ltd | Pyridine derivatives |
US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
IT1230859B (it) | 1989-06-05 | 1991-11-08 | Corvi Camillo Spa | 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
JPH05503517A (ja) | 1989-12-18 | 1993-06-10 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンド及びその用途 |
GB2244054B (en) | 1990-04-19 | 1994-04-06 | Ici Plc | Pyridine derivatives |
NZ238576A (en) | 1990-06-18 | 1994-12-22 | Merck & Co Inc | Pyridinone derivatives, preparation and pharmaceutical compositions thereof |
AU653734B2 (en) | 1990-06-19 | 1994-10-13 | Meiji Seika Kabushiki Kaisha | Substituted 4-biphenylmethoxypyridine derivatives |
NL9001752A (nl) | 1990-08-02 | 1992-03-02 | Cedona Pharm Bv | Nieuwe 1,4-dihydropyridinederivaten. |
IL99731A0 (en) | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
JPH05301872A (ja) | 1992-04-23 | 1993-11-16 | Kumiai Chem Ind Co Ltd | ピコリン酸誘導体及び除草剤 |
US5403816A (en) | 1990-10-25 | 1995-04-04 | Kumiai Chemical Industry Co., Ltd. | Picolinic acid derivative and herbicidal composition |
EP0498380A1 (de) | 1991-02-08 | 1992-08-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Komplexbildner |
JPH0641118A (ja) | 1991-05-31 | 1994-02-15 | Kumiai Chem Ind Co Ltd | ピコリン酸誘導体及び除草剤 |
US5185251A (en) | 1991-06-07 | 1993-02-09 | Merck & Co., Inc. | Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559 |
EP0591426A4 (en) | 1991-06-27 | 1996-08-21 | Univ Virginia Commonwealth | Sigma receptor ligands and the use thereof |
JP2600644B2 (ja) | 1991-08-16 | 1997-04-16 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体 |
FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5202243A (en) | 1991-10-04 | 1993-04-13 | Merck & Co., Inc. | Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices |
GB9203798D0 (en) | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
JPH07508527A (ja) | 1992-07-01 | 1995-09-21 | ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 錯体形成剤 |
US5290941A (en) | 1992-10-14 | 1994-03-01 | Merck & Co., Inc. | Facile condensation of methylbenzoxazoles with aromatic aldehydes |
EP0645387A1 (en) | 1993-04-07 | 1995-03-29 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivative and pharmaceutical composition containing the same |
DE4318550A1 (de) | 1993-06-04 | 1994-12-08 | Boehringer Mannheim Gmbh | Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
IL110151A (en) | 1993-06-30 | 1998-10-30 | Sankyo Co | Amid and urea histories and pharmaceutical preparations containing them |
JPH0725882A (ja) | 1993-07-07 | 1995-01-27 | Res Dev Corp Of Japan | アクロメリン酸bおよびeを製造するための中間体と、その製造方法 |
DK0637586T3 (da) | 1993-08-05 | 1999-12-06 | Hoechst Marion Roussel Inc | 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse |
EP0640609A1 (en) | 1993-08-24 | 1995-03-01 | Ono Pharmaceutical Co., Ltd. | Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
WO1995014015A1 (en) | 1993-11-19 | 1995-05-26 | Ciba-Geigy Ag | Benzothiophene derivatives possessing a methoxyimino substituent as microbicides |
EP0658559A1 (de) * | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
ES2145267T3 (es) | 1994-02-14 | 2000-07-01 | Merrell Pharma Inc | Nuevos derivados bisulfuro de mercaptoacetilamido de 1,3,4,5-tetrahidro-benzo(c)azepin-3-ona utiles como inhibidores de la encefalinasa y del enzima de conversion de la angiotensina. |
TW474813B (en) * | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
GB9420557D0 (en) | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
DE4442050A1 (de) | 1994-11-25 | 1996-05-30 | Hoechst Ag | Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien |
US5650408A (en) | 1995-06-07 | 1997-07-22 | Karanewsky; Donald S. | Thiazolo benzazepine containing dual action inhibitors |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
CA2238081A1 (en) | 1995-11-22 | 1997-05-29 | S. Jane Desolms | Inhibitors of farnesyl-protein transferase |
GB9604311D0 (en) | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
JP3895404B2 (ja) | 1996-05-17 | 2007-03-22 | 興和株式会社 | カルコン誘導体及びこれを含有する医薬 |
JP2000514041A (ja) | 1996-07-26 | 2000-10-24 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物 |
WO1998008818A1 (en) | 1996-08-26 | 1998-03-05 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
AU4136197A (en) | 1996-09-09 | 1998-03-26 | Kyowa Hakko Kogyo Co. Ltd. | Pyrrolocarbazole derivatives |
JP2001503762A (ja) | 1996-11-12 | 2001-03-21 | ノバルティス アクチェンゲゼルシャフト | 除草剤として有用なピラゾール誘導体 |
US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6043389A (en) | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
FR2761069A1 (fr) | 1997-03-20 | 1998-09-25 | Pf Medicament | Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments |
FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
US5760232A (en) | 1997-06-16 | 1998-06-02 | Schering Corporation | Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds |
US6214817B1 (en) | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
US6103723A (en) | 1997-10-17 | 2000-08-15 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP1023270A4 (en) | 1997-10-17 | 2001-04-18 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
HUP0301166A2 (en) | 1997-12-12 | 2003-08-28 | Euro Celtique Sa | 3-substituted adenines via2-thioxanthines |
KR20010041346A (ko) | 1998-02-25 | 2001-05-15 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 포스포리파제 a2 억제제 |
CA2319493A1 (en) | 1998-03-18 | 1999-09-23 | Regine Bohacek | Heterocyclic signal transduction inhibitors, compositions containing them |
US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
JP2002509918A (ja) | 1998-03-31 | 2002-04-02 | アケイディア ファーマスーティカルズ インコーポレイテッド | ムスカリン性レセプタに活性を有する化合物 |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
GB9810860D0 (en) | 1998-05-20 | 1998-07-22 | Hoechst Schering Agrevo Gmbh | Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides |
EP1090009A2 (en) | 1998-06-04 | 2001-04-11 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
YU41801A (sh) | 1998-12-14 | 2003-12-31 | F. Hofman - La Roche Ag. | Derivati fenilglicina |
US6544980B2 (en) | 1998-12-31 | 2003-04-08 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
CA2358955A1 (en) | 1998-12-31 | 2000-07-13 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
AU2871900A (en) | 1999-02-04 | 2000-08-25 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
RU2001126549A (ru) | 1999-03-31 | 2003-06-20 | БАСФ Акциенгезельшафт (DE) | Замещенные анилиновые соединения |
JP2000302757A (ja) | 1999-04-16 | 2000-10-31 | Shiseido Co Ltd | N−置換ピペリジン誘導体 |
US6251927B1 (en) | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
SK15522001A3 (sk) | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
JP2002544242A (ja) | 1999-05-14 | 2002-12-24 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 酵素活性化抗腫瘍プロドラッグ化合物 |
US6184228B1 (en) | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
EA005027B1 (ru) | 1999-06-28 | 2004-10-28 | Янссен Фармацевтика Н.В. | Ингибиторы репликации респираторно-синцитиального вируса |
JP4206212B2 (ja) | 1999-09-28 | 2009-01-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キヌクリジン化合物およびそれを有効成分として含有する医薬 |
SE9903759D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | Pharmaceutically active compounds |
CA2388240C (en) | 1999-11-05 | 2010-04-20 | Emisphere Technologies, Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
AUPQ407699A0 (en) | 1999-11-16 | 1999-12-09 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
CA2396079A1 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
WO2001057044A1 (fr) | 2000-02-01 | 2001-08-09 | Daiichi Pharmaceutical Co., Ltd. | Derives de pyrido-oxazine |
FR2804431A1 (fr) | 2000-02-02 | 2001-08-03 | Adir | Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6506755B2 (en) | 2000-02-03 | 2003-01-14 | Hoffmann-La Roche Inc. | Thiazolidinecarboxyl acids |
AUPQ585000A0 (en) | 2000-02-28 | 2000-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
MXPA02007603A (es) | 2000-03-09 | 2003-02-24 | Aventis Pharma Gmbh | Usos terapeuticos de mediadores ppar. |
US6559140B2 (en) | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
AU2001245823A1 (en) | 2000-03-17 | 2001-10-03 | Corixa Corporation | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
DK1303490T3 (da) | 2000-07-14 | 2008-08-25 | Hoffmann La Roche | N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater |
US20020142995A1 (en) | 2000-08-01 | 2002-10-03 | Nicolau Yves Claude | Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
US6638967B2 (en) | 2000-08-08 | 2003-10-28 | Ortho-Mcneil Phamraceutical, Inc. | Thiophene of furan pyrrolidine compounds |
US6653313B2 (en) | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
AUPR034000A0 (en) | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
IL155702A0 (en) | 2000-11-20 | 2003-11-23 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JPWO2002051849A1 (ja) | 2000-12-26 | 2004-04-22 | 第一製薬株式会社 | Cdk4活性阻害剤 |
EP1357115B1 (en) | 2000-12-28 | 2009-06-17 | Takeda Pharmaceutical Company Limited | Alkanoic acid derivatives, process for their production and use thereof |
US20040077654A1 (en) | 2001-01-15 | 2004-04-22 | Bouillot Anne Marie Jeanne | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
SE0100326D0 (sv) | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
US20030022923A1 (en) | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
SE0101324D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New process |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
EP1435894A4 (en) | 2001-07-23 | 2005-07-06 | Galileo Pharmaceuticals Inc | CYTOPROTECTIVE COMPOUNDS, METHODS AND PHARMACEUTICAL AND COSMETIC FORMULATIONS |
JP2003075970A (ja) | 2001-08-31 | 2003-03-12 | Konica Corp | ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法 |
KR100467313B1 (ko) | 2001-11-22 | 2005-01-24 | 한국전자통신연구원 | 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자 |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
CA2470931A1 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | Chalcone derivatives and their use to treat diseases |
US20030190333A1 (en) | 2002-02-04 | 2003-10-09 | Corixa Corporation | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins |
EP1492534B1 (en) | 2002-04-03 | 2008-06-25 | TopoTarget UK Limited | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
EP1542704A1 (en) | 2002-04-18 | 2005-06-22 | Stephen H. Embury | Method and composition for preventing pain in sickle cell patients |
US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
MXPA05001544A (es) * | 2002-08-08 | 2005-04-19 | Smithkline Beecham Corp | Compuestos de tiofeno. |
NZ538339A (en) | 2002-08-09 | 2007-01-26 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
MXPA05001590A (es) | 2002-08-09 | 2005-05-23 | Astrazeneca Ab | Compuestos que tienen actividad en los receptores metabotropicos de glutamato. |
EP1548008A4 (en) | 2002-08-23 | 2008-08-06 | Kirin Pharma Kk | COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION |
WO2004024705A1 (ja) | 2002-09-10 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 5員複素環化合物 |
GB0223712D0 (en) | 2002-10-14 | 2002-11-20 | Astrazeneca Ab | Chemical intermediate |
CA2507545C (en) | 2002-12-04 | 2011-06-21 | Virginia Commonwealth University | Use of furfural derivatives as anti-sickling agents |
US6908921B2 (en) | 2002-12-13 | 2005-06-21 | Merck & Co., Inc. | Quinoxalinone derivatives as bradykinin B1 antagonists |
AU2003303239A1 (en) | 2002-12-19 | 2004-07-14 | Atherogenics, Inc. | Process of making chalcone derivatives |
JP4679155B2 (ja) | 2002-12-25 | 2011-04-27 | キッセイ薬品工業株式会社 | 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
WO2004073675A1 (de) | 2003-02-24 | 2004-09-02 | Randolph Riemschneider | Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung |
GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
US20040186077A1 (en) | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
WO2004089410A1 (ja) | 2003-04-03 | 2004-10-21 | Kyowa Hakko Kogyo Co., Ltd. | 神経因性疼痛の予防及び/または治療剤 |
GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
CN1816529A (zh) | 2003-05-01 | 2006-08-09 | 布里斯托尔-迈尔斯.斯奎布公司 | 用作激酶抑制剂的芳基取代的吡唑-酰胺化合物 |
WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
EP1636205A1 (en) | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7211671B2 (en) | 2003-10-01 | 2007-05-01 | Bristol Myers Squibb Company | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
EP1670761B1 (en) | 2003-10-01 | 2009-01-28 | Xention Limited | Tetrahydro-naphthalene and urea derivatives |
WO2005042491A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
WO2005042467A1 (en) | 2003-10-31 | 2005-05-12 | Lica Pharmaceuticals A/S | Quaternary amino-functional chalcones |
EP2314576A1 (en) | 2003-11-05 | 2011-04-27 | F.Hoffmann-La Roche Ag | Phenyl derivatives as PPAR agonists |
CA2543913A1 (en) | 2003-11-10 | 2005-05-26 | Schering Aktiengesellschaft | Benzylether amine compounds useful as ccr-5 antagonists |
BRPI0417186A (pt) | 2003-12-02 | 2007-03-06 | Celgene Corp | método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica |
EP1555264A1 (en) | 2004-01-15 | 2005-07-20 | Sireen AG | Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase. |
US7378439B2 (en) | 2004-01-20 | 2008-05-27 | Usv, Ltd. | Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride |
AU2005211349A1 (en) | 2004-01-30 | 2005-08-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
GB0403038D0 (en) | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
BRPI0508532A (pt) | 2004-03-08 | 2007-08-07 | Wyeth Corp | moduladores do canal de ìon |
WO2005087748A1 (en) | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
CN1930161A (zh) | 2004-03-09 | 2007-03-14 | P·安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
WO2005086951A2 (en) | 2004-03-10 | 2005-09-22 | Threshold Pharmaceuticals, Inc. | Hypoxia-activated anti-cancer agents |
DE102004015226B3 (de) | 2004-03-24 | 2005-08-25 | Siemens Ag | Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung |
US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
JP2007533730A (ja) | 2004-04-20 | 2007-11-22 | アブ サイエンス | 筋炎および筋ジストロフィーを含む炎症性筋疾患を処置するためのc−kit阻害剤の使用法 |
WO2005102305A2 (en) | 2004-04-22 | 2005-11-03 | Allos Therapeutics, Inc. | Compositions of allosteric hemoglobin modifiers and methods of making the same |
WO2005102455A1 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating plasmodium related diseases |
WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
WO2005102346A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating fibrosis |
CA2566104A1 (en) | 2004-05-18 | 2005-12-01 | Ab Science | Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
WO2006003923A1 (ja) | 2004-06-30 | 2006-01-12 | Sankyo Company, Limited | 置換ベンゼン化合物 |
TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
JP2008517956A (ja) | 2004-10-28 | 2008-05-29 | メディキュア・インターナショナル・インコーポレーテッド | 二重の抗血小板性/抗凝固性ピリドキシン類似体 |
US20080287399A1 (en) | 2004-12-14 | 2008-11-20 | Astrazeneca Ab | Substituted Aminopyridines and Uses Thereof |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
US7858788B2 (en) | 2005-02-21 | 2010-12-28 | Shionogi & Co., Ltd. | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
BRPI0608714A2 (pt) | 2005-03-19 | 2010-01-26 | Amorepacific Corp | compostos, isÈmeros dos mesmos, ou sais farmaceuticamente aceitáveis dos mesmos como antagonista do receptor vanilóide, e composições farmacêuticas contendo os mesmos |
EP1864980A4 (en) | 2005-03-30 | 2010-08-18 | Eisai R&D Man Co Ltd | A PYRIDINE DERIVATIVE ANTIPILIC AGENT |
GB0506677D0 (en) | 2005-04-01 | 2005-05-11 | Btg Int Ltd | Iron modulators |
EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
JP2006306926A (ja) | 2005-04-26 | 2006-11-09 | Fuji Photo Film Co Ltd | 液晶組成物及び液晶素子 |
MX302718B (es) | 2005-04-28 | 2012-08-27 | Smithkline Beecham Corp | Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv. |
JP2008542352A (ja) | 2005-06-01 | 2008-11-27 | ビオアリアンス ファルマ | キノリン化合物及び他のhiv感染治療薬を含む相乗作用のコンビネーション |
WO2006130403A1 (en) | 2005-06-02 | 2006-12-07 | Bayer Cropscience Ag | Phenylalkyl substituted heteroaryl devivatives |
DE102005025989A1 (de) | 2005-06-07 | 2007-01-11 | Bayer Cropscience Ag | Carboxamide |
JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Hivインテグラーゼ阻害活性を有する多環性化合物 |
EP1896487A4 (en) | 2005-06-20 | 2010-03-31 | Astrazeneca Ab | PROCESS FOR THE PREPARATION OF OXABISPIDINE SULFONIC ACID SALTS |
NZ564759A (en) * | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
CN100562514C (zh) * | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
GB0516270D0 (en) | 2005-08-08 | 2005-09-14 | Glaxo Group Ltd | Novel compounds |
AU2006292603B2 (en) | 2005-09-16 | 2012-07-26 | Janssen Pharmaceutica N.V. | Process for the preparation of benzo (e) (1,2,4) triazepin-2-one derivatives |
ES2379987T3 (es) | 2005-10-11 | 2012-05-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compuestos de benzofurano marcados isotópicamente como radiotrazadores para proteínas amiloidógenas |
KR20080064182A (ko) | 2005-10-27 | 2008-07-08 | 시오노기세야쿠 가부시키가이샤 | Hiv 인테그라아제 억제활성을 가지는 다환성카르바모일피리돈 유도체 |
EP1948614A2 (en) | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
WO2007081630A2 (en) | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
WO2007084914A2 (en) | 2006-01-17 | 2007-07-26 | Neurocrine Biosciences, Inc. | Phenoxy-substituted pyrimidines as adenosine receptor antagonists |
WO2007095495A2 (en) | 2006-02-13 | 2007-08-23 | Pharmacopeia, Inc. | Benzodiazepine gcnf modulators for stem cell modulation |
EP1984334B1 (en) | 2006-02-15 | 2014-04-09 | Allergan, Inc. | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
US8013153B2 (en) | 2006-03-23 | 2011-09-06 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
US7351434B2 (en) | 2006-04-07 | 2008-04-01 | Academia Sinica | Therapeutic Gastrodia extracts |
RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
WO2007120760A2 (en) | 2006-04-13 | 2007-10-25 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
JP4963863B2 (ja) | 2006-04-27 | 2012-06-27 | 株式会社Adeka | 新規化合物及び該化合物を含有してなる液晶組成物 |
US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
WO2007146066A2 (en) | 2006-06-06 | 2007-12-21 | Critical Therapeutics, Inc. | Novel piperazines, pharmaceutical compositions and methods of use thereof |
TW200815425A (en) | 2006-06-08 | 2008-04-01 | Speedel Experimenta Ag | 2,5-disubstituted piperidines |
GB0614586D0 (en) | 2006-07-22 | 2006-08-30 | Pliva Istrazivacki Inst D O O | Pharmaceutical Formulation |
CN101113148A (zh) | 2006-07-26 | 2008-01-30 | 中国海洋大学 | 二氧哌嗪类化合物及其制备方法和用途 |
MX2009000925A (es) | 2006-07-27 | 2009-02-05 | Amorepacific Corp | Compuestos novedosos, isomero de los mismos, o sales farceuticamente aceptables de los mismos como antagonistas receptor de vanilloide; y composiciones farmaceuticas que contienen el mismo. |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
PL2061749T3 (pl) | 2006-09-03 | 2018-11-30 | Techfields Biochem Co. Ltd | Dodatnio naładowane, rozpuszczalne w wodzie proleki acetaminofenu i związków pokrewnych o bardzo dużej szybkości przenikania przez skórę |
CA2663436A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
EP2097385B1 (en) | 2006-10-23 | 2012-08-01 | Merck Sharp & Dohme Corp. | 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydroclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands |
FR2909379B1 (fr) | 2006-11-30 | 2009-01-16 | Servier Lab | Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
EP2123637A4 (en) | 2006-11-30 | 2011-12-21 | Tokyo Inst Tech | NEW CURCUMINE DERIVATIVE |
TW200835687A (en) | 2006-11-30 | 2008-09-01 | R Tech Ueno Ltd | Thiazole derivatives and their use as VAP-1 inhibitor |
DE102006060598A1 (de) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
JP2010515750A (ja) | 2007-01-11 | 2010-05-13 | アラーガン インコーポレイテッド | スフィンゴシン−1−ホスフェート(s1p)受容体アンタゴニスト生物活性を有する6−置換インドール−3−カルボン酸アミド化合物 |
US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
US8557853B2 (en) | 2007-02-09 | 2013-10-15 | Allergan, Inc. | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents |
EP2125734A2 (en) | 2007-02-22 | 2009-12-02 | Syngeta Participations AG | Novel microbiocides |
TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽b2受體調節劑 |
WO2008121066A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | Novel tricyclic spiropiperidines or spiropyrrolidines and their use as modulators of chemokine receptors |
US7994367B2 (en) | 2007-05-22 | 2011-08-09 | Sumitomo Chemical Company, Limited | Method for producing benzaldehyde compound |
RU2479577C2 (ru) | 2007-05-25 | 2013-04-20 | Эбботт Гмбх Унд Ко.Кг | Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2) |
WO2009001214A2 (en) | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
AU2008277783B2 (en) | 2007-07-17 | 2012-09-20 | F. Hoffmann-La Roche Ag | Inhibitors of 11beta-hydroxysteroid dehydrogenase |
US8143253B2 (en) | 2007-07-26 | 2012-03-27 | Novartis Ag | Organic compounds |
TW200918521A (en) | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
ES2393430T3 (es) | 2007-10-17 | 2012-12-21 | Novartis Ag | Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK |
JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
KR20120102117A (ko) | 2007-12-04 | 2012-09-17 | 에프. 호프만-라 로슈 아게 | 아이속사졸로-피리딘 유도체 |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
JP2009203230A (ja) | 2008-01-31 | 2009-09-10 | Daiichi Sankyo Co Ltd | ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物 |
CA2716514A1 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
WO2009106599A2 (en) | 2008-02-29 | 2009-09-03 | Novartis Ag | Substituted piperidines as therapeutic compounds |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
CN102137837A (zh) | 2008-04-11 | 2011-07-27 | 株式会社医药分子设计研究所 | Pai-1抑制剂 |
US8633245B2 (en) | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
EP2291349A2 (en) | 2008-04-14 | 2011-03-09 | The Board of Regents of The University of Texas System | Small molecule inhibitors of the pleckstrin homology domain and methods for using same |
JP2011136906A (ja) | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
WO2009136889A1 (en) * | 2008-05-08 | 2009-11-12 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
AU2009253812A1 (en) | 2008-06-04 | 2009-12-10 | Ambrilia Biopharma Inc. | HIV integrase inhibitors from pyridoxine |
DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
JP5314330B2 (ja) | 2008-06-16 | 2013-10-16 | 住友化学株式会社 | 2−(アリールオキシメチル)ベンズアルデヒドの製造方法およびその中間体 |
GB0811451D0 (en) * | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
EP2303859A4 (en) | 2008-06-20 | 2012-08-22 | Metabolex Inc | ARYL GPR119 AGONISTS AND USES THEREOF |
KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
EP2331541B1 (en) | 2008-09-04 | 2015-04-22 | Boehringer Ingelheim International GmbH | Indolizine inhibitors of leukotriene production |
JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
CA2738663A1 (en) | 2008-10-03 | 2010-04-08 | Schering Corporation | Spiro-imidazolone derivatives as glucagon receptor antagonists |
PT2356109T (pt) | 2008-10-10 | 2017-03-10 | Vm Discovery Inc | Composições e métodos para o tratamento distúrbios de utilização de álcool, dor e outras doenças |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
US8815875B2 (en) | 2008-11-12 | 2014-08-26 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (FABP) |
US8846664B2 (en) | 2008-11-12 | 2014-09-30 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
MX2011006000A (es) | 2008-12-08 | 2011-07-20 | Boehringer Ingelheim Int | Compuestos para tratar cancer. |
WO2010073011A2 (en) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
PT2385938E (pt) | 2009-01-12 | 2015-06-02 | Pfizer Ltd | Derivados de sulfonamida |
US8822462B2 (en) | 2009-01-28 | 2014-09-02 | Emory University | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions |
WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
TW201033201A (en) * | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
CN101838264B (zh) | 2009-03-16 | 2014-12-03 | 住友化学株式会社 | 化合物、光学膜和光学膜的制造方法 |
JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
SI3222277T1 (sl) | 2009-03-31 | 2021-02-26 | Ligand Pharmaceuticals Inc. | Bifenilsulfonamidni antagonist receptorja endotelina in angiotensina II za zdravljenje glomeruloskleroze in z IgA povzročene nefropatije |
US8367654B2 (en) | 2009-05-08 | 2013-02-05 | Tetraphase Pharmaceuticals, Inc. | 8-AZA tetracycline compounds |
JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
WO2011024869A1 (ja) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
EP2474540A4 (en) | 2009-08-31 | 2013-03-13 | Nippon Chemiphar Co | GPR119 AGONIST |
CA2773561A1 (en) | 2009-09-14 | 2011-03-17 | Phusis Therapeutics Inc. | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
EP2480533A1 (en) | 2009-09-21 | 2012-08-01 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
FI2498756T4 (fi) | 2009-11-09 | 2023-03-22 | Neratinibimaleaatin tablettiformulaatiot | |
TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
AU2011208357A1 (en) | 2010-01-25 | 2012-08-09 | Kareus Therapeutics Sa | Novel compositions for reducing Abeta 42 production and their use in treating Alzheimer's Disease (AD) |
US20130178453A1 (en) | 2010-02-09 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | Cannabinoid Agonists |
WO2011100324A1 (en) | 2010-02-09 | 2011-08-18 | Ironwood Pharmaceuticals Inc. | Cannabinoid receptor agonists |
JP5375644B2 (ja) | 2010-02-10 | 2013-12-25 | 住友化学株式会社 | 組成物及び光学フィルム |
JP2013523645A (ja) | 2010-03-25 | 2013-06-17 | メルク・シャープ・エンド・ドーム・コーポレイション | グルカゴン受容体拮抗薬としての新規なスピロイミダゾロン類、組成物およびそれらの使用方法 |
CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
KR101698153B1 (ko) | 2010-04-26 | 2017-01-23 | 광주과학기술원 | P2x1 및 p2x3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물 |
CN102232949A (zh) | 2010-04-27 | 2011-11-09 | 孙远 | 提高药物溶出度的组合物及其制备方法 |
TWI535442B (zh) | 2010-05-10 | 2016-06-01 | Kyowa Hakko Kirin Co Ltd | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine |
CA2800618C (en) | 2010-05-26 | 2018-08-28 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
JP5703594B2 (ja) | 2010-05-26 | 2015-04-22 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
US20130116231A1 (en) | 2010-07-12 | 2013-05-09 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
EP2816035A3 (en) | 2010-09-14 | 2015-02-25 | Instytut Biochemii I Biofizyki Polskiej Akademii Nauk | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction |
CN102116772B (zh) | 2010-09-28 | 2013-08-28 | 上海大学 | 二氢查尔酮化合物的筛选方法 |
EP2630135B1 (en) | 2010-10-21 | 2020-03-04 | Bayer Intellectual Property GmbH | 1-(heterocyclic carbonyl) piperidines |
MX2013004279A (es) | 2010-10-21 | 2013-06-05 | Bayer Ip Gmbh | 1-(heterociclo carbonil)-pirrolidinas 2-sustituidas. |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
BR112013014875A2 (pt) | 2010-12-27 | 2016-10-18 | Takeda Pharmaceutical | tablete oralmente desintegrável |
US8703941B2 (en) | 2011-01-10 | 2014-04-22 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
EP2670245B1 (en) | 2011-02-04 | 2015-09-09 | The Scripps Research Institute | Alpha-ketoheterocycles and methods of making and using |
WO2012138981A2 (en) | 2011-04-06 | 2012-10-11 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
CN103717588B (zh) | 2011-04-11 | 2016-08-03 | 绿色科技株式会社 | 吡唑衍生物 |
KR20140093610A (ko) | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
JP6170043B2 (ja) | 2011-07-01 | 2017-07-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ジヒドロピラゾール |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
EP3333164B1 (en) | 2011-07-29 | 2023-06-07 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
WO2013040471A2 (en) | 2011-09-15 | 2013-03-21 | Demerx, Inc. | Noribogaine salt ansolvates |
WO2013052803A2 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
JP6242810B2 (ja) * | 2011-12-28 | 2017-12-06 | グローバル・ブラッド・セラピューティクス・インコーポレイテッドGlobal Blood Therapeutics,Inc. | 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法 |
CN104582705A (zh) | 2012-01-10 | 2015-04-29 | 林伯士艾瑞斯公司 | 白介素-1受体相关激酶(irak)抑制剂和其用途 |
SG11201408150UA (en) | 2012-06-14 | 2015-01-29 | Janssen Biotech Inc | Treatment of pluripotent cells |
WO2013192517A2 (en) | 2012-06-21 | 2013-12-27 | Whitehead Institute For Biomedical Research | Compounds for treating infectious diseases |
JP2014005380A (ja) | 2012-06-25 | 2014-01-16 | Dic Corp | 液晶組成物 |
US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2014011906A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US9085586B2 (en) | 2012-07-11 | 2015-07-21 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
KR102148355B1 (ko) | 2012-07-27 | 2020-08-26 | 사토 파머슈티컬 가부시키가이샤 | 디플루오로메틸렌 화합물 |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
BR112015003729A2 (pt) | 2012-08-24 | 2018-06-05 | Univ Texas | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente |
WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
WO2014031933A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
TW201416348A (zh) | 2012-08-29 | 2014-05-01 | Gruenenthal Chemie | 以氟甲基取代之吡咯甲醯胺 |
ES2643571T3 (es) | 2012-09-27 | 2017-11-23 | Chugai Seiyaku Kabushiki Kaisha | Gen de fusión FGFR3 y fármaco que se dirige al mismo |
US9560850B2 (en) | 2012-12-27 | 2017-02-07 | Sumitomo Chemical Company, Limited | Tetrazolinone compound and use thereof |
US9073946B2 (en) | 2013-01-15 | 2015-07-07 | Kineta, Inc. | Anti-viral compounds |
WO2014130856A2 (en) | 2013-02-21 | 2014-08-28 | Wayne Rothbaum | Treatment of skeletal-related disorders |
US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
CN105246477A (zh) | 2013-03-15 | 2016-01-13 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
BR112015021980A2 (pt) | 2013-03-15 | 2017-07-18 | Global Blood Therapeutics Inc | compostos e seus usos para a modulação de hemoglobina |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CA2903220C (en) | 2013-03-15 | 2023-01-24 | Qing Xu | Aldehyde compounds and uses thereof for the modulation of hemoglobin |
WO2014150256A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
US8952171B2 (en) * | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
MX2015011448A (es) | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
WO2014150261A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulaton of hemoglobin |
US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
KR20140127587A (ko) | 2013-04-25 | 2014-11-04 | (주)프론트바이오 | 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
US20160108031A1 (en) | 2013-04-30 | 2016-04-21 | Heinrich-Heine-Universitat Dusseldorf | Inhibitors of nhr2 and/or runx1/eto-tetramerization |
WO2014194245A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
WO2014194242A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Flt3 inhibitors and uses thereof |
US20160206604A1 (en) | 2013-08-26 | 2016-07-21 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
WO2015031285A1 (en) | 2013-08-27 | 2015-03-05 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
US9920073B2 (en) | 2013-10-04 | 2018-03-20 | Drexel University | Compositions useful for inhibiting HIV-1 infection and methods using same |
US9663718B2 (en) | 2013-10-21 | 2017-05-30 | Merck Patent Gmbh | Method of preparing a birefringent polymer film |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN103936658B (zh) | 2013-12-12 | 2016-01-13 | 石家庄诚志永华显示材料有限公司 | 含有咔唑结构单元的化合物及其制备方法与应用 |
CN103936659B (zh) | 2013-12-12 | 2016-06-22 | 石家庄诚志永华显示材料有限公司 | 含有碳桥联咔唑结构单元的化合物及其制备方法与应用 |
KR20150070027A (ko) | 2013-12-16 | 2015-06-24 | 메르크 파텐트 게엠베하 | 액정 매질 |
US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
DK3110420T3 (da) | 2014-02-25 | 2019-05-13 | Board Of Regents Univ Of Texas System | Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme |
CA2941663C (en) | 2014-03-06 | 2020-02-18 | Shanghai Haiyan Pharmaceutical Technology Co. Ltd | Piperidine derivatives as orexin receptor antagonist |
US20150258106A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of substance abuse |
US20150258105A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of alcohol dependence |
US20150258104A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Use of noribogaine for the treatment of pain |
TWI648282B (zh) | 2014-03-27 | 2019-01-21 | 印度商托仁特生技有限公司 | 新熔合咪唑苯并噻唑化合物 |
BR112016028845B1 (pt) | 2014-06-17 | 2023-04-04 | Chiesi Farmaceutici S.P.A. | Composto, composição farmacêutica e uso de um composto |
WO2016043849A2 (en) | 2014-07-24 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds for treating acute respiratory distress syndrome or a negative effect thereof |
KR102452385B1 (ko) | 2014-07-28 | 2022-10-07 | 메르크 파텐트 게엠베하 | 호메오트로픽 정렬을 갖는 액정 매질 |
EP2985334B1 (en) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Liquid-crystalline medium |
KR102474637B1 (ko) | 2014-09-30 | 2022-12-05 | 트랜지션즈 옵티칼 인코포레이티드 | 자외선 광 흡수제 |
KR20170065637A (ko) | 2014-10-07 | 2017-06-13 | 세이지 테라퓨틱스, 인크. | 신경활성 화합물 및 그의 사용 방법 |
WO2016077541A1 (en) | 2014-11-12 | 2016-05-19 | The Trustees Of The University Of Pennsylvania | Novel anti-infective compounds and methods using same |
ES2955490T3 (es) | 2014-11-26 | 2023-12-01 | Demerx Inc | Métodos y composiciones para potenciar la acción de los analgésicos opioides mediante el uso de alcaloides de la iboga |
BR112017017619A2 (pt) | 2015-02-19 | 2018-05-08 | Purdue Pharma Lp | métodos e composições para diminuir esvaziamento gástrico |
US10647679B2 (en) | 2015-03-15 | 2020-05-12 | Emory University | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto |
WO2016153951A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | 5-deutero-thiazolidinyldione compounds and methods of treating medical disorders using same |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
CN104876912B (zh) | 2015-04-08 | 2017-07-21 | 苏州云轩医药科技有限公司 | Wnt信号通路抑制剂及其应用 |
WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017039318A1 (en) | 2015-09-01 | 2017-03-09 | Kainos Medicine, Inc. | Benzimidazole derivatives for dna methylation inhibitors |
EP3350181B1 (en) | 2015-09-02 | 2023-11-01 | The Regents of The University of California | Her3 ligands and uses thereof |
WO2017040963A1 (en) | 2015-09-03 | 2017-03-09 | Forma Therapeutics, Inc. | [6,6] fused bicyclic hdac8 inhibitors |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
EP4219449A3 (en) | 2016-03-16 | 2023-10-11 | Kura Oncology, Inc. | Substituted indole derivatives and methods of preparation thereof |
WO2017184531A1 (en) | 2016-04-18 | 2017-10-26 | Demerx, Inc. | Treatment of movement-related disorders using noribogaine |
TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
BR112018076812A2 (pt) | 2016-06-21 | 2021-09-28 | The University Of Melbourne | Ativadores da latência de hiv |
US11746097B2 (en) | 2016-06-24 | 2023-09-05 | Saint Louis University | LXR inverse agonists for treatment of cancer |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
MX2021005887A (es) | 2018-11-19 | 2021-09-14 | Global Blood Therapeutics Inc | Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina. |
-
2014
- 2014-03-10 CA CA2903220A patent/CA2903220C/en active Active
- 2014-03-10 SG SG10201802911RA patent/SG10201802911RA/en unknown
- 2014-03-10 AP AP2015008721A patent/AP2015008721A0/xx unknown
- 2014-03-10 US US14/776,726 patent/US20160083343A1/en not_active Abandoned
- 2014-03-10 PE PE2015001922A patent/PE20161035A1/es unknown
- 2014-03-10 EA EA201591432A patent/EA034922B1/ru unknown
- 2014-03-10 CN CN202010996640.8A patent/CN112500338A/zh active Pending
- 2014-03-10 AU AU2014237340A patent/AU2014237340C1/en active Active
- 2014-03-10 SG SG11201507320QA patent/SG11201507320QA/en unknown
- 2014-03-10 MY MYPI2015002271A patent/MY191087A/en unknown
- 2014-03-10 EP EP14770695.6A patent/EP2970196B1/en active Active
- 2014-03-10 CN CN201480015944.4A patent/CN105073728A/zh not_active Withdrawn
- 2014-03-10 MX MX2015011445A patent/MX2015011445A/es unknown
- 2014-03-10 ES ES14770695T patent/ES2852054T3/es active Active
- 2014-03-10 BR BR112015021985-3A patent/BR112015021985B1/pt active IP Right Grant
- 2014-03-10 WO PCT/US2014/022769 patent/WO2014150268A1/en active Application Filing
- 2014-03-10 JP JP2016501058A patent/JP6426694B2/ja active Active
- 2014-03-10 KR KR1020157024781A patent/KR102280614B1/ko active IP Right Grant
- 2014-03-13 TW TW103109178A patent/TWI695830B/zh active
- 2014-03-13 UY UY0001035426A patent/UY35426A/es not_active Application Discontinuation
-
2015
- 2015-09-02 IL IL241060A patent/IL241060B/en unknown
- 2015-09-07 CL CL2015002501A patent/CL2015002501A1/es unknown
- 2015-09-09 SA SA515361026A patent/SA515361026B1/ar unknown
- 2015-09-09 SA SA517382253A patent/SA517382253B1/ar unknown
-
2017
- 2017-06-02 ZA ZA2017/03791A patent/ZA201703791B/en unknown
-
2018
- 2018-09-11 US US16/127,776 patent/US20190010121A1/en not_active Abandoned
- 2018-10-25 JP JP2018200506A patent/JP6690861B2/ja active Active
- 2018-11-06 AU AU2018260808A patent/AU2018260808B2/en active Active
- 2018-11-09 US US16/186,275 patent/US11053195B2/en active Active
-
2020
- 2020-04-07 JP JP2020069169A patent/JP2020105228A/ja active Pending
- 2020-06-12 AU AU2020203882A patent/AU2020203882A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015021985A2 (pt) | compostos e seus usos para a modulação de hemoglobina | |
BR112015021982A2 (pt) | compostos e seus usos para a modulação de hemoglobina | |
BR112015021986A2 (pt) | compostos e seus usos para a modulação de hemoglobina | |
US4267194A (en) | Calcium derivatives of taurine having reinforced neuro-muscular activity | |
RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
JP7028474B2 (ja) | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 | |
BR0104228A (pt) | Derivados do ácido de alquilamino úteis como agentes farmacêuticos, método para fabricação de um composto, composição farmacêutica, métodos para tratamentos diversos e uso de um composto na fabricação de um medicamento para tratamentos diversos | |
RU2000131220A (ru) | Новые аналоги жирных кислот для лечения первичного и вторичного рестеноза | |
EP1503768A1 (en) | Inositol pyrophosphates, and methods of use thereof | |
EP1753714A2 (en) | 2-substituted and 4-substituted aryl nitrone compouds | |
Mislankar et al. | 6-[18F] fluorometaraminol. A radiotracer for in vivo mapping of adrenergic nerves of the heart | |
ATE16191T1 (de) | Stabile salze von s-adenosinylmethionin, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen welche als aktive substanz diese derivate enthalten. | |
US6610702B2 (en) | Ammonium salts of inositol hexaphosphate, and uses thereof | |
BRPI0708613B1 (pt) | Uso de compostos de amônio quaternário, e composição farmacêutica | |
KR890017246A (ko) | 크로만 유도체 | |
BR112020007858A2 (pt) | composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto | |
JPS6379832A (ja) | 新規治療剤 | |
US20150258112A1 (en) | Methods and compositions for treating depression using ibogaine | |
RU2005135428A (ru) | Поглощение макромолекул | |
RU95114673A (ru) | Производные алкилбензоилгуанидина | |
ATE23995T1 (de) | Pyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
BR0318533A (pt) | azolidinacarbonitrilas e seu uso como inibidores de dpp-iv | |
EP3960179A1 (en) | Method for treating cough by using diaminopyrimidine compound | |
JPS60222494A (ja) | オキサザホスホリン誘導体の塩及びその製法 | |
NO167147C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive tetrahydroisoksazolo(4,5-c)pyridinderivater. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: GLOBAL BLOOD THERAPEUTICS, INC. (US) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2014, OBSERVADAS AS CONDICOES LEGAIS |